Share

May 1, 1998; 50 (5 Suppl 5)

Share

A

  1. Adler, Charles H.

    1. COMT inhibitionA new treatment strategy for Parkinson's disease
      Matthias C. Kurth, Charles H. Adler

B

  1. Baas, H.

    1. Catechol-O-methyltransferase inhibition with tolcapone reduces the"wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients
      H. Baas, A. G. Beiske, J. Ghika, M. Jackson, W. H. Oertel, W. Poewe, G. Ransmayr

  2. Bailey, P.

    1. Tolcapone in stable Parkinson's diseaseEfficacy and safety of long-term treatment
      C. H. Waters, M. Kurth, P. Bailey, L. M. Shulman, P. LeWitt, E. Dorflinger, D. Deptula, S. Pedder, Tolcapone Stable Study Group

  3. Beiske, A. G.

    1. Catechol-O-methyltransferase inhibition with tolcapone reduces the"wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients
      H. Baas, A. G. Beiske, J. Ghika, M. Jackson, W. H. Oertel, W. Poewe, G. Ransmayr

C

  1. Chase, Thomas N.

    1. Levodopa therapyConsequences of the nonphysiologic replacement of dopamine
      Thomas N. Chase

D

  1. Deptula, D.

    1. Tolcapone in stable Parkinson's diseaseEfficacy and safety of long-term treatment
      C. H. Waters, M. Kurth, P. Bailey, L. M. Shulman, P. LeWitt, E. Dorflinger, D. Deptula, S. Pedder, Tolcapone Stable Study Group

  2. Dorflinger, E.

    1. Tolcapone in stable Parkinson's diseaseEfficacy and safety of long-term treatment
      C. H. Waters, M. Kurth, P. Bailey, L. M. Shulman, P. LeWitt, E. Dorflinger, D. Deptula, S. Pedder, Tolcapone Stable Study Group
    2. Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenonA double-blind, placebo-controlled, multicenter trial
      A. H. Rajput, W. Martin, M. H. Saint-Hilaire, E. Dorflinger, S. Pedder

F

  1. Fahn, Stanley

    1. TolcaponeCOMT inhibition for the treatment of Parkinson's disease
      Stanley Fahn

G

  1. Ghika, J.

    1. Catechol-O-methyltransferase inhibition with tolcapone reduces the"wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients
      H. Baas, A. G. Beiske, J. Ghika, M. Jackson, W. H. Oertel, W. Poewe, G. Ransmayr

  2. Goetz, Christopher G.

    1. Influence of COMT inhibition on levodopa pharmacology and therapy
      Christopher G. Goetz
    2. Highlights of the North American and European experiences
      Christopher G. Goetz

J

  1. Jackson, M.

    1. Catechol-O-methyltransferase inhibition with tolcapone reduces the"wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients
      H. Baas, A. G. Beiske, J. Ghika, M. Jackson, W. H. Oertel, W. Poewe, G. Ransmayr

  2. Jorga, Karin M.

    1. Pharmacokinetics, pharmacodynamics, and tolerability of tolcaponeA review of early studies in volunteers
      Karin M. Jorga

K

  1. Kurth, M.

    1. Tolcapone in stable Parkinson's diseaseEfficacy and safety of long-term treatment
      C. H. Waters, M. Kurth, P. Bailey, L. M. Shulman, P. LeWitt, E. Dorflinger, D. Deptula, S. Pedder, Tolcapone Stable Study Group

  2. Kurth, Matthias C.

    1. COMT inhibitionA new treatment strategy for Parkinson's disease
      Matthias C. Kurth, Charles H. Adler

L

  1. LeWitt, P.

    1. Tolcapone in stable Parkinson's diseaseEfficacy and safety of long-term treatment
      C. H. Waters, M. Kurth, P. Bailey, L. M. Shulman, P. LeWitt, E. Dorflinger, D. Deptula, S. Pedder, Tolcapone Stable Study Group

M

  1. Martin, W.

    1. Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenonA double-blind, placebo-controlled, multicenter trial
      A. H. Rajput, W. Martin, M. H. Saint-Hilaire, E. Dorflinger, S. Pedder

O

  1. Oertel, W. H.

    1. Catechol-O-methyltransferase inhibition with tolcapone reduces the"wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients
      H. Baas, A. G. Beiske, J. Ghika, M. Jackson, W. H. Oertel, W. Poewe, G. Ransmayr

P

  1. Pedder, S.

    1. Tolcapone in stable Parkinson's diseaseEfficacy and safety of long-term treatment
      C. H. Waters, M. Kurth, P. Bailey, L. M. Shulman, P. LeWitt, E. Dorflinger, D. Deptula, S. Pedder, Tolcapone Stable Study Group
    2. Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenonA double-blind, placebo-controlled, multicenter trial
      A. H. Rajput, W. Martin, M. H. Saint-Hilaire, E. Dorflinger, S. Pedder

  2. Poewe, W.

    1. Catechol-O-methyltransferase inhibition with tolcapone reduces the"wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients
      H. Baas, A. G. Beiske, J. Ghika, M. Jackson, W. H. Oertel, W. Poewe, G. Ransmayr

R

  1. Rajput, A. H.

    1. Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenonA double-blind, placebo-controlled, multicenter trial
      A. H. Rajput, W. Martin, M. H. Saint-Hilaire, E. Dorflinger, S. Pedder

  2. Ransmayr, G.

    1. Catechol-O-methyltransferase inhibition with tolcapone reduces the"wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients
      H. Baas, A. G. Beiske, J. Ghika, M. Jackson, W. H. Oertel, W. Poewe, G. Ransmayr

S

  1. Saint-Hilaire, M. H.

    1. Tolcapone improves motor function in parkinsonian patients with the"wearing-off" phenomenonA double-blind, placebo-controlled, multicenter trial
      A. H. Rajput, W. Martin, M. H. Saint-Hilaire, E. Dorflinger, S. Pedder

  2. Shulman, L. M.

    1. Tolcapone in stable Parkinson's diseaseEfficacy and safety of long-term treatment
      C. H. Waters, M. Kurth, P. Bailey, L. M. Shulman, P. LeWitt, E. Dorflinger, D. Deptula, S. Pedder, Tolcapone Stable Study Group

W

  1. Waters, C. H.

    1. Tolcapone in stable Parkinson's diseaseEfficacy and safety of long-term treatment
      C. H. Waters, M. Kurth, P. Bailey, L. M. Shulman, P. LeWitt, E. Dorflinger, D. Deptula, S. Pedder, Tolcapone Stable Study Group
Back to top
Subscribe to e-Alerts
RSS
Advertisement
Advertisement